Anbio Biotechnology (NNNN) — SEC Filings
Anbio Biotechnology (NNNN) — 6 SEC filings. Latest: 20-F/A (Apr 9, 2026). Includes 3 6-K, 2 20-F, 1 20-F/A.
View Anbio Biotechnology on SEC EDGAR
Overview
Anbio Biotechnology (NNNN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 20-F/A filed on Apr 9, 2026: Anbio Biotechnology filed an amended annual report (20-F/A) for the period ending December 31, 2025. The filing, accepted on April 9, 2026, includes various XBRL documents detailing financial information. The company's principal executive offices are located in Frankfurt am Main, Germany.
Sentiment Summary
Across 6 filings, the sentiment breakdown is: 6 neutral. The dominant filing sentiment for Anbio Biotechnology is neutral.
Filing Type Overview
Anbio Biotechnology (NNNN) has filed 1 20-F/A, 2 20-F, 3 6-K with the SEC between Feb 2025 to Apr 2026.
Filings by Year
Recent SEC Filings (6)
| Date | Form | Description | Risk |
|---|---|---|---|
| Apr 9, 2026 | 20-F/A | Anbio Biotechnology Files Amended 20-F Annual Report | medium |
| Apr 7, 2026 | 20-F | Anbio Biotechnology Files 2025 Annual Report | medium |
| Dec 30, 2025 | 6-K | Anbio Biotechnology Reports H1 2025 Financials | low |
| Nov 13, 2025 | 6-K | 6-K Filing | |
| Apr 28, 2025 | 20-F | Anbio Biotechnology Files 2024 Annual Report | medium |
| Feb 21, 2025 | 6-K | Anbio Biotechnology Announces IPO Details | medium |
Risk Profile
Risk Assessment: Of NNNN's 5 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 1 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Top Tags
annual-report (3) · biotechnology (3) · amended-filing (1) · financials (1) · 20-F (1) · foreign-issuer (1) · financial-results (1) · 6-k (1) · 20-f (1) · ipo (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Fiscal Year End | 2025-12-31 | The period covered by the annual report. |
| Filing Date | 2026-04-09 | Date the amended 20-F/A was accepted by the SEC. |
| FORM 20-F size | 1169205 | Size of the main 20-F filing document in bytes. |
| Complete submission text file size | 4222023 | Total size of the complete submission text file in bytes. |
| Class A Ordinary Shares | 1,600,000 | Number of shares to be sold in the IPO |
Frequently Asked Questions
What are the latest SEC filings for Anbio Biotechnology (NNNN)?
Anbio Biotechnology has 6 recent SEC filings from Feb 2025 to Apr 2026, including 3 6-K, 2 20-F, 1 20-F/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NNNN filings?
Across 6 filings, the sentiment breakdown is: 6 neutral. The dominant sentiment is neutral.
Where can I find Anbio Biotechnology SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Anbio Biotechnology (NNNN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Anbio Biotechnology?
Financial highlights for Anbio Biotechnology are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for NNNN?
Investment thesis data for NNNN will be available once enriched filings are processed.
Who are the key executives at Anbio Biotechnology?
Executive information for Anbio Biotechnology is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Anbio Biotechnology stock?
Of NNNN's 5 assessed filings, 0 were flagged high-risk, 4 medium-risk, and 1 low-risk.
What are recent predictions and forward guidance from Anbio Biotechnology?
Forward guidance and predictions for Anbio Biotechnology are extracted from SEC filings as they are enriched.